Michael A. Davies

Research interests

Publications

• Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

  Nature Medicine · 2021 · https://doi.org/10.1038/s41591-021-01406-6

• Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

  Nature Medicine · 2021 · https://doi.org/10.1038/s41591-020-01188-3

• Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

  Science · 2021 · 10.1126/science.aaz7015

• Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

  Nature Genetics · 2021 · https://doi.org/10.1038/s41588-020-00750-6

• B cells and tertiary lymphoid structures promote immunotherapy response

  Nature · 2020 · https://doi.org/10.1038/s41586-019-1922-8

• Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1904059

• Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy

  Cell Metabolism · 2018 · https://doi.org/10.1016/j.cmet.2018.02.024

• Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

  Clinical Cancer Research · 2018 · https://doi.org/10.1158/1078-0432.ccr-18-1116

• Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30015-9

• Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

  Science Translational Medicine · 2017 · 10.1126/scitranslmed.aah3560

• Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma

  npj Genomic Medicine · 2017 · https://doi.org/10.1038/s41525-017-0013-8

• Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

  Science · 2017 · https://doi.org/10.1126/science.aan4236

• Future perspectives in melanoma research

  Journal of Translational Medicine · 2016 · https://doi.org/10.1186/s12967-016-1070-y

• Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

  Cancer Discovery · 2016 · https://doi.org/10.1158/2159-8290.cd-15-1545

• Genomic Classification of Cutaneous Melanoma

  Cell · 2015 · https://doi.org/10.1016/j.cell.2015.05.044

• Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.60.4165

• Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

  Cancer Discovery · 2015 · https://doi.org/10.1158/2159-8290.cd-15-0283

• Pathways and therapeutic targets in melanoma

  Oncotarget · 2014 · https://doi.org/10.18632/oncotarget.1892

• Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma

  Cancer Research · 2014 · https://doi.org/10.1158/0008-5472.can-14-1392

• A Landscape of Driver Mutations in Melanoma

  Cell · 2012 · https://doi.org/10.1016/j.cell.2012.06.024

• Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

  Clinical Cancer Research · 2012 · https://doi.org/10.1158/1078-0432.ccr-12-1632

• Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

  The Lancet Oncology · 2012 · 10.1016/s1470-2045(12)70431-x

• BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

  Clinical Cancer Research · 2012 · https://doi.org/10.1158/1078-0432.ccr-12-1626

• An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

  Cancer Research · 2008 · https://doi.org/10.1158/0008-5472.can-07-6854

Current projects

No projects listed.